ProCE Banner Activity

ANDES: Generic Fixed-Dose DRV/RTV in Combination With 3TC vs 3TC/TDF for Initial HIV Treatment

Slideset Download
Conference Coverage
Dual therapy was well tolerated and demonstrated noninferior efficacy vs triple therapy as first-line ART in this open-label, randomized trial conducted in Argentina.

Released: August 05, 2022

Expiration: August 04, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare


IAS 2021

ProCE Banner